Loading...
ESMO congress Solid Tumors 20202025-01-28T16:59:50+01:00

ESMO 2020 Solid Tumors – virtual

 

Lecture Board: Emiliano Calvo, MD, PhD; Andrés Cervantes, MD, PhD; Ronan Kelly, MD, MBA; Christian Schauer, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from ESMO 2020 Solid Tumors – virtual

ESMO 2020 Solid Tumors English Slide Kit

Slide Kit PD-1/PD-L1 and PARP inhibition on GI and ovarian cancers

ESMO 2020 Solid Tumors English

Full report (english)

ESMO Solid Tumours 2020 Mandarin

Full report (mandarin)

EXPERT VIDEOS

All videointerviews from ESMO Solid Tumors 2020

Andrés Cervantes talks about novel findings obtained in the field of gastric cancer, gastroesophageal junction adenocarcinoma and esophageal cancer as well as developments in hepatocellular carcinoma and investigational immunotherapies that might evolve into new treatment approaches.

Eric Van Cutsem gives an overview of practice-changing results obtained for gastrointestinal cancers including colorectal cancer, gastric cancer and esophageal cancer and describes progress that has recently been made with respect to certain biomarkers.

The ESMO congress has provided amazing new data on gastroesophageal cancer, and great contributions by different authors all over the world have been presented. Patients with advanced gastric cancer used to have a median overall survival of less than 1 year when treated with conventional chemo­therapy. For the first time, this was prolonged to more than 1 year due to the ­addition of checkpoint inhibition.

Andrés Cervantes • MD • PhD, Department of Medical Oncology, Hospital Clinic Universitario, Biomedical Research institute INCLIVA, University of Valencia, Spain
Go to Top